Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections
Qing Lei(Huazhong University of Science and Technology), Xionglin Fan(Huazhong University of Science and Technology), Jun‐biao Xue(Shanghai Jiao Tong University), Bo Zhang(Tongji Hospital), Shenghai Huang(Anhui Medical University), Yun-xiao Zheng(Shanghai Jiao Tong University), Huan Qi(Qingdao Institute of Bioenergy and Bioprocess Technology), Zhaowei Xu(Shanghai Jiao Tong University), Caizheng Yu(Huazhong University of Science and Technology), Sheng‐ce Tao(Shanghai Jiao Tong University), Xuening Wang(Shanxi Medical University), He‐wei Jiang(Shanghai Jiao Tong University), Ziyong Sun(Tongji Hospital), Yandi Zhang(Liaoning Normal University), Hong Chen(Shanghai Jiao Tong University), Feng Wang(Tongji Hospital), Yang Li(Shanghai Jiao Tong University), Hainan Zhang(Shanghai Jiao Tong University), Xiaosong Lin(Huazhong University of Science and Technology), Hongyan Hou(Tongji Hospital), Zongjie Yao(Huazhong University of Science and Technology), Shujuan Guo(Shanghai Jiao Tong University), Zhuqing Ouyang(Huazhong University of Science and Technology)
Cited by 16
Related Papers
The laboratory tests and host immunity of COVID-19 patients with different severity of illness
|JCI Insight|2020|576
Detection of IgM and IgG antibodies in patients with coronavirus disease 2019
|Clinical & Translational Immunology|2020|415
Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids
|Protein & Cell|2020|397
Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014
|Clinical Microbiology and Infection|2016|376
SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70
|Cellular and Molecular Immunology|2020|376